Menu Search
Equities

Ono Pharmaceutical Co Ltd

ON4:BER

Ono Pharmaceutical Co Ltd

Actions
  • Price (EUR)11.00
  • Today's Change-0.10 / -0.90%
  • Shares traded3.00
  • 1 Year change-31.25%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.

  • Revenue in JPY (TTM)484.30bn
  • Net income in JPY95.13bn
  • Incorporated1947
  • Employees3.85k
  • Location
    Ono Pharmaceutical Co Ltd1-8-2, Kyutaro-machi, Chuo-kuOSAKA-SHI 541-8564JapanJPN
  • Phone+81 662635670
  • Fax+81 662632976
  • Websitehttps://www.ono-pharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4528:TYO since
announced		Transaction
value
Deciphera Pharmaceuticals IncDeal completed29 Apr 202429 Apr 2024Deal completed-20.15%2.29bn
Data delayed at least 20 minutes, as of Nov 13 2024 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.